---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-006266"
form_type: "8-K"
ticker: "FBLG"
cik: "0001958777"
company_name: "FibroBiologics, Inc."
filed_at: "2024-02-14T23:59:59+00:00"
generated_at: "2026-06-06T02:43:25.138982+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# FibroBiologics preclinical data: HDF spheroids cut psoriasis severity 35% in mice

## Summary
- Presented at 2024 Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases.
- Single IV dose of HDF spheroids reduced average PASI score by 35% (p<0.0001) in IMQ-induced psoriasis mouse model.
- Spheroids also ameliorated IMQ-induced spleen enlargement and normalized lymphocyte and monocyte counts.
- In vitro, HDFs inhibited TNF-α and IL-17 and suppressed dendritic cell maturation via CD40/CD80/CD86 downregulation.
- Company holds 150+ issued/pending patents; data supports IND-enabling studies for early-discovery psoriasis program.

## SEC filing metadata
- accession: 0001493152-24-006266
- form_type: 8-K
- ticker: FBLG
- cik: 0001958777
- company_name: FibroBiologics, Inc.
- filed_at: 2024-02-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1958777/000149315224006266/0001493152-24-006266-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1958777/000149315224006266/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-006266
- JSON: https://secwatch.observer/filing/0001493152-24-006266.json
- Plain text: https://secwatch.observer/filing/0001493152-24-006266.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.